Clearside Biomedical Earnings Call Transcripts
Fiscal Year 2025
-
The session highlighted advances in suprachoroidal drug delivery, growing clinical adoption, and the differentiated profile of CLS-AX for wet AMD. Phase III trials are designed for regulatory alignment and real-world relevance, with ongoing efforts to secure funding for further development.
-
Leaders in suprachoroidal drug delivery are advancing a phase III-ready asset for wet AMD, aiming for 3–6 month dosing intervals and leveraging strong phase II data. Phase III trials will align with real-world practice, with over 50% of patients expected to reach six-month intervals.
-
The session highlighted advances in suprachoroidal drug delivery for retinal diseases, with a focus on the phase 3-ready CLS-AX for wet AMD and ongoing global partnerships. The company is optimizing trial design, expanding its pipeline, and actively seeking funding to support late-stage development.
-
The conference highlighted leadership in suprachoroidal drug delivery, with CLS-AX advancing to phase 3 for wet AMD after strong phase 2b results. Flexible dosing, safety, and strategic partnerships set the program apart, while pipeline expansion targets geographic atrophy with novel approaches.
Fiscal Year 2024
-
Positive phase II-B results for CLS-AX in wet AMD led to FDA alignment on pivotal phase III trials. Cash reserves fund operations into Q4 2025, with additional funding sought for phase III. Multiple global partnerships and regulatory milestones expand the suprachoroidal platform.
-
Phase II-B Odyssey trial in wet AMD showed strong efficacy and safe repeat dosing in a challenging patient group. Flexible dosing every three to six months and a superior safety profile via suprachoroidal delivery set the stage for a broad phase III in treatment-naive patients, with phase III launch expected in late 2025.
-
Positive phase 2b results for CLS-AX in wet AMD support phase 3 advancement, with strong safety, efficacy, and flexible dosing. Cash reserves of $23.6M fund operations into Q3 2025, and strategic partnerships and pipeline expansion continue to progress.
-
The ODYSSEY phase IIb trial in wet AMD met its primary endpoint, showing CLS-AX maintained stable vision, reduced injection frequency by 84%, and demonstrated strong durability and safety in a difficult-to-treat population. No severe adverse events were reported.
-
Suprachoroidal delivery is validated as a safe, versatile platform with real-world and clinical data supporting its use in retinal diseases. CLS-AX for wet AMD is advancing, with phase II-B data expected in Q3 2024, and future plans include targeting geographic atrophy and gene therapy partnerships.